Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 18,411 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Not applicable Interventional

Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes

NCT00496106
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Telephone counseling, Telephone interview
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

NCT02606058
View directory record Official record
Conditions
Preterm Birth
Interventions
Deferred cord clamping
Procedure
Lead sponsor
University of Sydney
Other
Eligibility
Female only
Enrollment
1,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Houston, Texas • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

NCT00214058
View directory record Official record
Conditions
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Carboplatin, Docetaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Timeline
2002 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 30, 2026, 4:44 PM EDT
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose, Intranasal Oxytocin (IN-OXT) 24 IU single dose, Placebo single dose
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Prehabilitation for Adults With End Stage Renal Disease on the Kidney Transplant Waitlist

NCT02895243
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Prehabilitation
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00004915
View directory record Official record
Conditions
Endometrial Cancer
Interventions
raloxifene
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 30, 2026, 4:44 PM EDT
Terminated No phase listed Observational

Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

NCT00571415
View directory record Official record
Conditions
Cervix Cancer
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Using sipIT Tools to Increase Compliance With Fluid Consumption Guidelines in Urolithiasis-Prone Subjects

NCT03787615
View directory record Official record
Conditions
Urolithiasis
Interventions
sipIT tools
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 30, 2026, 4:44 PM EDT
Recruiting Phase 2 Interventional

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

NCT02989025
View directory record Official record
Conditions
Pregnancy, Preeclampsia (PE)
Interventions
17 OHPC
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

NCT00786838
View directory record Official record
Conditions
Solid Tumor
Interventions
Trabectedin, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Charlotte, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NICU2HOME+: Supporting Illinois Families

NCT04480255
View directory record Official record
Conditions
Premature Birth, NICU, Premature, Infant
Interventions
Group 1: Standard of Care, Group 2: NICU2HOME+ app
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Arlington Heights, Illinois • Chicago, Illinois • Winfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 30, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional

Targeted Fortification of Donor Breast Milk in Preterm Infants

NCT04294368
View directory record Official record
Conditions
Prematurity; Extreme, Failure to Thrive in Newborn, Growth Retardation, Growth Failure, Infant Nutrition Disorders
Interventions
Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid, Similac Liquid Protein Fortifier, Nestle Microlipid, Medica Nutrition SolCarb, Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification), Similac Liquid Protein Fortifier (Targeted Fortification), Nestle Microlipid (Targeted Fortification), Medica Nutrition SolCarb (Targeted Fortification), Analysis with Miris (AB) Human Milk Analyzer
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
1 Day to 21 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

NCT06111768
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
Dapagliflozin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

NCT01406548
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 30, 2026, 4:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01962948
View directory record Official record
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
paclitaxel, ganetespib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 30, 2026, 4:44 PM EDT
Recruiting Phase 1 Interventional

Botox for Chronic Pelvic Pain

NCT06796985
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Botulinum neurotoxin, High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Drug · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 1 Interventional

Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer

NCT00516243
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
placebo, quality-of-life assessment, questionnaire administration, laboratory biomarker analysis, defined green tea catechin extract
Other · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 30, 2026, 4:44 PM EDT
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 30, 2026, 4:44 PM EDT
Completed No phase listed Observational

Improving Prematurity-Related Respiratory Outcomes at Vanderbilt

NCT01460576
View directory record Official record
Conditions
Preterm Birth, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 7 Days
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Jackson, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia

NCT00520455
View directory record Official record
Conditions
Pregnancy
Interventions
levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Oct 30, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia

NCT00150826
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Quinapril, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 30, 2026, 4:44 PM EDT
Not listed Phase 2 Interventional

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

NCT05453825
View directory record Official record
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions
navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
Biological
Lead sponsor
OncXerna Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 30, 2026, 4:44 PM EDT